Actively Recruiting
Pulmonary Condensate: A Promising Source of Proteomic Biomarkers for Non-invasive Evaluation of Pulmonary Involvement in Asthma and Cystic Fibrosis
Led by The Institute of Molecular and Translational Medicine, Czech Republic · Updated on 2026-03-23
450
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
Sponsors
T
The Institute of Molecular and Translational Medicine, Czech Republic
Lead Sponsor
U
University Hospital Olomouc
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are exploring non-invasive ways to detect lung injury, inflammation, and infections in chronic lung diseases such as cystic fibrosis (CF) and bronchial asthma (AB). This study focuses on collecting exhaled breath condensate (EBC) to identify unique molecular "breathprints" that indicate pulmonary inflammation and bacterial infections, particularly from pathogens like Pseudomonas aeruginosa. The goal is to link these breathprints with disease severity and respiratory microbiota in CF and AB patients. Participants include children and adults with moderate or IgE-mediated asthma, individuals with cystic fibrosis, and healthy controls without lung disease. Breath condensate samples will be collected and analyzed using high-resolution mass spectrometry to identify biomarkers. The study tracks changes before and after treatments such as antibiotics for CF and inhaled corticosteroids or bronchodilators for asthma, assessing lung disease activity and treatment effects. During the 18 months following screening, participants will undergo lung function tests, blood tests for enzymes like amylase and lipase, microbiological cultures, and imaging scans including CT and X-rays for CF patients. Researchers will monitor inflammatory biomarkers and respiratory health, aiming to validate EBC as a useful diagnostic and monitoring tool. The study involves healthy volunteers and offers a detailed look at pulmonary conditions without invasive procedures.
CONDITIONS
Brief Title
Pulmonary Condensate: Non-invasive Evaluation of Pulmonary Involvement in Asthma and Cystic Fibrosis.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Children or adults with moderate or IgE-mediated asthma
- Children or adults diagnosed with cystic fibrosis
- Healthy children or adults without lung disorders
You will not qualify if you...
History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 18 months
Participants provide exhaled breath condensate samples for biomarker analysis to evaluate pulmonary involvement in asthma and cystic fibrosis.
Periodic visits for breath condensate collection and clinical assessments depending on participant group
Duration - Up to 18 months
Participants are monitored over time to assess lung function and disease activity through various clinical measurements and imaging.
Multiple assessments including lung function tests and imaging as per clinical schedule
Trial Site Locations
Total: 1 location
1
University Hospital Olomouc
Olomouc, Czechia, 77900
Actively Recruiting
Research Team
P
Petr Dzubak, MD, PhD.
M
Marian Hajduch, MD, PhD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here